Immutep Raises A$10 Million Via Private Placement and Underwritten Entitlement Offer
July 09, 2019 08:00 ET
|
Immutep Limited
NEW YORK, July 09, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “Company”), an Australian biotechnology company developing novel immunotherapy treatments for...
Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer
June 25, 2019 08:00 ET
|
Immutep Limited
226 patients with metastatic breast cancer have been enrolled in the AIPAC studyCombination of eftilagimod alpha, an antigen presenting cell (APC) activator, administered in combination with...
Immutep to Host Key Opinion Leader Call
June 24, 2019 14:36 ET
|
Immutep Limited
NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and...
Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy
June 21, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, June 21, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial
June 13, 2019 08:00 ET
|
Immutep Limited
Recruitment for 2nd line (PD-1 refractory) NSCLC and 2nd line HNSCC cohorts of the TACTI-002 trial, conducted in collaboration with MSD, are ongoingInitial data from the TACTI-002 study expected...
INSIGHT: First Patient Dosed in the 4th arm called “INSIGHT-004”
June 06, 2019 08:00 ET
|
Immutep Limited
Highlights First patient received first dose in INSIGHT-004, a phase I clinical trialEvaluates the combination of eftilagimod alpha with avelumab (BAVENCIO®) in different cancer indicationsPatient...
Immutep Presentation at ASCO 2019
June 03, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, June 03, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep Announces European Patent Grant for Eftilagimod Alpha in Chemo-Immunotherapy
May 23, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, May 23, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma
May 17, 2019 08:00 ET
|
Immutep Limited
Presented at the World Advanced Therapies & Regenerative Medicine Congress & Expo 2019 SYDNEY, Australia, May 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP)...
Immutep Announces Upcoming Industry Conference Participation
May 10, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, May 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...